文献速递前列腺癌

整合基因组前列腺评分与CAPRA/CAPRA-S预测根治性前列腺切除术后生化复发

Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy.
PubMed 文献 · Eur Urol Oncol · 2026-04-11

本研究纳入955例根治性前列腺切除术前接受Oncotype DX检测的患者,开发了将CAPRA或CAPRA-S与GPS整合的CAPRA-G和CAPRA-SG评分。GPS独立预测BCR(p<0.001),整合后C-index从0.67升至0.76(p<0.001)和从0.81升至0.84(p=0.041)。

要点

  • GPS独立于CAPRA和CAPRA-S预测生化复发(p<0.001)。
  • CAPRA-G和CAPRA-SG分别将GPS按1/6和1/10权重整合,提升区分度。
  • 决策曲线分析显示整合评分在临床相关阈值(约0.05-0.45)净获益更高。

核心结论

  • GPS整合可增强根治性前列腺切除术后BCR风险分层,CAPRA-G和CAPRA-SG将基因组风险量化为简便临床工具。

研究设计与样本

  • 回顾性队列分析955例根治性前列腺切除术前接受Oncotype DX检测的患者,中位随访60个月(IQR 36-72)。

主要发现

  • GPS独立预测BCR(p<0.001);1个CAPRA和CAPRA-S分分别对应约6和10个GPS分,得出CAPRA-G=CAPRA+GPS/6和CAPRA-SG=CAPRA-S+GPS/10。
  • CAPRA-G较CAPRA的C-index从0.67升至0.76(p<0.001),CAPRA-SG较CAPRA-S从0.81升至0.84(p=0.041)。
  • 决策曲线分析显示CAPRA-G和CAPRA-SG在临床相关阈值(约0.05-0.45)净获益更高。

关键数值与推荐

  • GPS预测BCR独立于CAPRA或CAPRA-S(p<0.001)。
  • CAPRA-G和CAPRA-SG的C-index分别为0.76和0.84,较原评分显著改善(p<0.001和p=0.041)。
  • 决策曲线分析阈值约0.05-0.45。

临床怎么用

  • 对于根治性前列腺切除术前接受GPS检测的患者,可用CAPRA-G和CAPRA-SG量化基因组风险以改善BCR风险分层。

局限性

  • 缺乏外部验证;因选择性GPS处方导致高危疾病代表性不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Cancer of the Prostate Risk Assessment (CAPRA) score and its postsurgical variant (CAPRA-S) predict biochemical recurrence (BCR) after radical prostatectomy (RP) but do not capture tumor biology. We developed two integrated clinical scores, CAPRA-G and CAPRA-SG, combining CAPRA or CAPRA-S with Genomic Prostate Score (GPS). METHODS: We analyzed 955 patients with Oncotype DX testing before RP. Associations between GPS, CAPRA, and CAPRA-S scores, and BCR were assessed using Cox models. CAPRA-G and CAPRA-SG were derived from β-coefficient weighting. Model discrimination was evaluated using Harrell's C-index (3000 bootstrap resamples); differences were assessed with a nonparametric U-statistic. Decision-curve analysis compared CAPRA with CAPRA-G and CAPRA-S with CAPRA-SG. KEY FINDINGS AND LIMITATIONS: Median follow-up was 60 mo (IQR 36-72). GPS predicted BCR independent of CAPRA or CAPRA-S (p < 0.001). Using log-hazard β-coefficients, one CAPRA and CAPRA-S point corresponded to » 6 and 10 GPS points, respectively, yielding CAPRA-G = CAPRA + GPS/6 and CAPRA-SG = CAPRA-S + GPS/10. Compared with CAPRA and CAPRA-S, CAPRA-G and CAPRA-SG showed a statistically significant improvement in C-indices, increasing from 0.67 to 0.76 (p < 0.001) and from 0.81 to 0.84 (p = 0.041), respectively. Decision-curve analysis demonstrated higher net benefit for CAPRA-G and CAPRA-SG at clinically relevant thresholds (» 0.05-0.45). Limitations included lack of external validation and under-representation of high-risk disease due to selective GPS prescription. CONCLUSIONS AND CLINICAL IMPLICATIONS: GPS integration enhances BCR risk stratification in the RP setting. CAPRA-G and CAPRA-SG scores quantify genomic risk and translate GPS into simple, clinically applicable tools with improved clinical utility. External validation is warranted.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ozawa Y, Moschovas MC, Sandri M, et al. Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy. Eur Urol Oncol. 2026. PMID: 41966955. doi:10.1016/j.euo.2026.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。